Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK-3 Inhibition with Lithium and Divalproex in Alzheimer's Disease
NCT00088387Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lithium in Alzheimer's disease (AD) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Cerebrospinal Fluid Phosphorylated Tau Epitopes (Threonine-181 and Threonine-231) at 6 weeks. Started Jul 2004; status: completed.
02
Drugs
lithium
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00088387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088387.